Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) was the target of a large growth in short interest in March. As of March 29th, there was short interest totalling 2,341,967 shares, a growth of 20.1% from the March 15th total of 1,949,841 shares. Based on an average daily volume of 724,027 shares, the short-interest ratio is currently 3.2 days. Currently, 2.0% of the company’s stock are sold short.

Several analysts have issued reports on the company. Maxim Group set a $3.00 price target on Actinium Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, February 5th. Zacks Investment Research raised shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research note on Monday, April 1st. Finally, Oppenheimer set a $5.00 price objective on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, February 26th. Five research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $3.50.

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in shares of Actinium Pharmaceuticals by 6.4% in the third quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after purchasing an additional 154,403 shares during the last quarter. Vanguard Group Inc grew its stake in shares of Actinium Pharmaceuticals by 6.4% in the third quarter. Vanguard Group Inc now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after acquiring an additional 154,403 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Actinium Pharmaceuticals by 23.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,031,210 shares of the biotechnology company’s stock valued at $399,000 after acquiring an additional 198,480 shares in the last quarter. Finally, Virtu Financial LLC increased its position in Actinium Pharmaceuticals by 103.1% during the third quarter. Virtu Financial LLC now owns 195,623 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 99,318 shares during the period.

Shares of ATNM stock traded up $0.02 on Tuesday, reaching $0.58. The stock had a trading volume of 663,411 shares, compared to its average volume of 776,807. Actinium Pharmaceuticals has a 12 month low of $0.33 and a 12 month high of $0.87.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06).

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.watchlistnews.com/short-interest-in-actinium-pharmaceuticals-inc-atnm-increases-by-20-1/2951327.html.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.

Recommended Story: What is a front-end load?

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.